Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480921 | 0.74 | SYK (0.36) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL2647129 | 0.73 | FNTA (0.31) | — | |
| SCHEMBL28652329 | 0.72 | KMT2A (0.37) | KDM4EHSD17B10KMT2AGAA | |
| SCHEMBL3568027 | 0.71 | HTT (0.51) | CYP11B1CYP11B2ALDH1A1KDM4ERAB9A | |
| SCHEMBL28645658 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4EGAA | |
| SCHEMBL3275833 | 0.70 | CYP11B1 (0.43) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL1097298 | 0.69 | CYP19A1 (0.41) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL25311885 | 0.67 | CYP11B1 (0.48) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4489945 | 0.67 | CYP11B1 (0.48) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6598800 | 0.67 | PDE5A (0.40) | ALDH1A1KDM4EHSD17B10KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | KSANDER GARY MICHAEL | 2009-10-22 | — | — | US | disclosed |
| EP-2057163-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264420-A1 | ORGANIC COMPOUNDS | CYP17A1, CYP11B1, CYP46A1 | CYP11B1 2/4885CYP11B2 11/4885SMN1; SMN2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.